Nasal blockage induced by oral administration of non-steroidal anti-inflammatory drugs in a guinea-pig model of allergic rhinitis

Journal of Pharmacological Sciences

Volumn 105, Issue 3, 2007, Pages 251-257

  Hai, Yan Han ^a   Nabe, Takeshi ^a   Mizutani, Nobuaki ^a   Fujii, Masanori ^a   Terada, Tetsuya ^b   Takenaka, Hiroshi ^b   Kohno, Shigekatsu ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Aspirin; Cysteinyl leukotriene; Indomethacin; Nasal blockage; Prostaglandin E2

Indexed keywords

ACETYLSALICYLIC ACID; ALLERGEN; DICLOFENAC; INDOMETACIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PRANLUKAST; PROSTAGLANDIN E2; PROSTAGLANDIN INHIBITOR;

ALLERGIC RHINITIS; ANIMAL EXPERIMENT; ARTICLE; BREATHING RATE; DOSE RESPONSE; DRUG SENSITIVITY; HYPERSENSITIVITY; MALE; NONHUMAN;

EID: 36348996121     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0070973     Document Type: Article

References (28)

1. Widal MF, Abrami P, Lenmoyez J. Anaphylaxie et idiosyncrasie. Presse Med. 1922;30:189-192.
2. Pfaar O, Klimek L. Eicosanoids, aspirin-intolerance and the upper airways - Current standards and recent improvements of the desensitization therapy. J Physiol Pharmacol. 2006;57 Suppl 12:5-13.
3. Szczeklik A, Sanak M, Niz E, Kielbasa B. Aspirin intolerance and the cyclooxygenase-leukotriene pathways. Curr Opin Pulm Med. 2004;10:51-56.
4. Szczeklik A, Stevenson DD. Aspirin-induced asthma: Advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol. 2003;111:913-921.
5. Babu KS, Salvi S. Aspirin and asthma. Chest. 2000;118:1470-1478.
6. Pfaar O, Klimek L. Aspirin desensitization in aspirin intolerance: update on current standards and recent improvements. Curr Opin Allergy Clin Immunol. 2006;6:161-166.
7. Nabe T, Shimizu K, Mizutani N, Saeki Y, Yamamura H, Takenaka H, et al. A new model of experimental allergic rhinitis using Japanese cedar pollen in guinea pigs. Jpn J Pharmacol. 1997;75:243-251.
8. Nabe T, Mizutani N, Shimizu K, Takenaka H, Kohno S. Development of pollen-induced rhinitis with early and late phase nasal blockage in guinea pigs. Inflamm Res. 1998;47:369-374.
9. Mizutani N, Nabe T, Sasaki K, Takenaka H, Kohno S. Nasal hyperresponsiveness to histamine induced by repetitive exposures to cedar pollen in guinea pigs. Eur Respir J. 1999;14:1368-1375.
10. Mizutani N, Nabe T, Imai A, Sakurai H, Takenaka H, Kohno S. Markedly increased nasal blockage by intranasal leukotriene D4 in an experimental allergic rhinitis model: Contribution of dilated mucosal blood vessels. Jpn J Pharmacol. 2001;86:170-182.
11. Nabe T, Shinoda N, Yamashita K, Yamada M, Yamamura H, Kohno S. Comparative studies on nebulizers for antigen inhalation in experimental asthma. Allergol Int. 1997;46:261-267.
12. Pennock BE, Cox CP, Rogers RM, Cain WA, Wells JH. A noninvasive technique for measurement of changes in specific airway resistance. J Appl Physiol. 1979;46:399-406.
13. Iijima H, Ishii M, Yamauchi K, Chao C-L, Kimura K, Shimura S, et al. Bronchoalveolar lavage and histologic characterization of late asthmatic response in guinea pigs. Am Rev Respir Dis. 1987;136:922-929.
14. Curnock AP, Robson PA, Yea CM, Moss D, Gadher S, Thomson TA, et al. Potencies of leflunomide and HR325 as inhibitors of prostaglandin endoperoxide H synthase-1 and -2: Comparison with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 1997;282:339-347.
15. Chan C-C, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)- furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Phramacological and biochemical profiles. J Pharmacol Exp Ther. 1999;290:551-560.
16. Oliw E, Lundén I, Anggärd E. In vivo inhibition of prostaglandin synthesis in rabbit kidney by non-steroidal antiinflammatory drugs. Acta Pharmacol Toxicol (Copenh). 1978;42:179-184.
17. Inoue K, Fujisawa H, Motonaga A, Inoue Y, Kyoi T, Ueda F, et al. Anti-inflammatory effects of etodolac: comparison with other non-steroidal anti-inflammatory drugs. Biol Pharm Bull. 1994;17:1577-1583.
18. Micheletto C, Tognella S, Visconti M, Pomari C, Trevisan F, Dal Negro RW. Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo. Allergy. 2004;59:289-294.
19. Lee DK, Haggart K, Robb FM, Lipworth BJ. Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Eur Respir J. 2004;24:226-230.
20. 2 receptor antagonist on mediator-controlled resistance in guinea pigs. Eur J Pharmacol. 2000;403:169-179.
21. Fujita M, Yonetomi Y, Takeda H, Nakagawa N, Kawabata K, Ohno H. Effects of a specific cysteinyl leukotriene antagonist, pranlukast, on antigen-induced cysteinyl leukotriene-mediated rhinitis in guinea pigs. Jpn J Pharmacol. 1997;75:347-353.
22. Nakagawa N, Obata T, Kobayashi T, Okada Y, Nambu F, Terawaki T, et al. In vivo Pharmacologic profile of ONO-1078: a potent, selective and orally active peptide leukotriene (LT) antagonist. Jpn J Pharmacol. 1992;60:217-225.
23. Dahlén B, Nizankowska E, Szczeklik A, Zetterström O, Bochenek G, Kumlin M, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med. 1998;157:1187-1194.
24. Wasiak W, Szmidt M. A six week double blind, placebo controlled, crossover study of the effect of misoprostol in the treatment of aspirin sensitive asthma. Thorax. 1999;54:900-904.
25. 2 on allergic airway responses in the rats. J Immunol. 2002;169:3963-3969.
26. Roberts II LJ, Morrow JD. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, Goodman Gilman A, editors. Goodman & Gilman's The pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001. p. 687-731.
27. Claria J, Serhan CN. Aspirin triggers previously undescribed eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A. 1995;92:9475-9479.
28. 4 are potent inhibitors of acute inflammation. Receptors and pathways. Adv Exp Med Biol. 1999;447:133-149.